Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.
2.

Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.

Gu YL, Kampinga MA, Wieringa WG, Fokkema ML, Nijsten MW, Hillege HL, van den Heuvel AF, Tan ES, Pundziute G, van der Werf R, Hoseyni Guyomi S, van der Horst IC, Zijlstra F, de Smet BJ.

Circulation. 2010 Dec 21;122(25):2709-17. doi: 10.1161/CIRCULATIONAHA.110.002741. Epub 2010 Nov 15.

3.

Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials.

Navarese EP, Kozinski M, Obonska K, Margheri M, Gurbel PA, Kubica J, De Luca G.

Platelets. 2012;23(4):274-81. doi: 10.3109/09537104.2011.619602. Epub 2011 Oct 11.

PMID:
21988317
4.
5.

Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.

De Luca G, Verdoia M, Suryapranata H.

Atherosclerosis. 2012 Jun;222(2):426-33. doi: 10.1016/j.atherosclerosis.2012.02.041. Epub 2012 Mar 7. Review.

PMID:
22483166
6.

Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.

Thiele H, Schindler K, Friedenberger J, Eitel I, Fürnau G, Grebe E, Erbs S, Linke A, Möbius-Winkler S, Kivelitz D, Schuler G.

Circulation. 2008 Jul 1;118(1):49-57. doi: 10.1161/CIRCULATIONAHA.107.747642. Epub 2008 Jun 16.

7.

Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study.

Bertrand OF, Rodés-Cabau J, Larose E, Rinfret S, Gaudreault V, Proulx G, Barbeau G, Déry JP, Gleeton O, Manh-Nguyen C, Noël B, Roy L, Costerousse O, De Larochellière R; EArly Discharge after Transradial Stenting of CoronarY Arteries in Acute Myocardial Infarction (EASY-MI) Study Investigators.

Am J Cardiol. 2010 Jun 1;105(11):1520-7. doi: 10.1016/j.amjcard.2010.01.006. Epub 2010 Apr 14.

PMID:
20494655
8.

Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.

Iversen A, Abildgaard U, Galloe A, Hansen PR, Galatius S, Madsen JK, Engstroem T, Pedersen S, Jensen KS, Jensen JS.

J Interv Cardiol. 2011 Apr;24(2):105-11. doi: 10.1111/j.1540-8183.2010.00616.x. Epub 2010 Dec 22.

PMID:
21175845
10.

Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.

Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G; Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators.

Am Heart J. 2010 Apr;159(4):547-54. doi: 10.1016/j.ahj.2009.12.038.

PMID:
20362711
11.

Meta-analysis of randomized controlled trials comparing intracoronary and intravenous administration of glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction.

Wang Y, Wu B, Shu X.

Am J Cardiol. 2012 Apr 15;109(8):1124-30. doi: 10.1016/j.amjcard.2011.11.053. Epub 2012 Jan 14. Review.

PMID:
22245413
12.

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

Thiele H, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G.

Lancet. 2012 Mar 10;379(9819):923-31. doi: 10.1016/S0140-6736(11)61872-2. Epub 2012 Feb 21.

PMID:
22357109
13.

Aborted myocardial infarction in intracoronary compared with standard intravenous abciximab administration in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Eitel I, Desch S, Schindler K, Fuernau G, Schuler G, Thiele H.

Int J Cardiol. 2011 Nov 17;153(1):21-5. doi: 10.1016/j.ijcard.2010.08.027. Epub 2010 Sep 6.

PMID:
20817283
14.

Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial.

Brener SJ, Witzenbichler B, Maehara A, Dizon J, Fahy M, El-Omar M, Dambrink JH, Genereux P, Mehran R, Oldroyd K, Parise H, Gibson CM, Stone GW.

Am Heart J. 2013 Jul;166(1):64-70. doi: 10.1016/j.ahj.2013.03.029. Epub 2013 Apr 30.

PMID:
23816023
15.

Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.

Rakowski T, Siudak Z, Dziewierz A, Birkemeyer R, Legutko J, Mielecki W, Depukat R, Janzon M, Stefaniak J, Zmudka K, Dubiel JS, Partyka L, Dudek D.

Am Heart J. 2009 Oct;158(4):569-75. doi: 10.1016/j.ahj.2009.08.008.

PMID:
19781416
16.

Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.

Kubica J, Koziński M, Navarese EP, Tantry US, Grześk G, Fabiszak T, Kubica A, Świątkiewicz I, Bliden KP, Gurbel PA.

Cardiol J. 2012;19(3):230-42. Review.

17.

Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.

Zeymer U, Margenet A, Haude M, Bode C, Lablanche JM, Heuer H, Schröder R, Kropff S, Bourkaib R, Banik N, Zahn R, Teiger E.

J Am Coll Cardiol. 2010 Aug 3;56(6):463-9. doi: 10.1016/j.jacc.2009.08.093.

19.

Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.

Eitel I, Wöhrle J, Suenkel H, Meissner J, Kerber S, Lauer B, Pauschinger M, Birkemeyer R, Axthelm C, Zimmermann R, Neuhaus P, Brosteanu O, de Waha S, Desch S, Gutberlet M, Schuler G, Thiele H.

J Am Coll Cardiol. 2013 Apr 2;61(13):1447-54. doi: 10.1016/j.jacc.2013.01.048. Epub 2013 Feb 27.

20.

Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions.

Kubica A, Kozinski M, Navarese EP, Grzesk G, Goch A, Kubica J.

Curr Med Res Opin. 2011 Nov;27(11):2133-44. doi: 10.1185/03007995.2011.621417. Epub 2011 Sep 26. Review.

PMID:
21942506

Supplemental Content

Support Center